Applications of MTPA (Mosher) Amides of Secondary Amines: Assignment of Absolute Configuration in Chiral Cyclic Amines
摘要:
Mosher's MTPA (methoxy(trifluoromethyl)phenylacetyl) technology is applied to the assignment of absolute configuration of several synthetic and natural chiral amines. The substrates are cyclic, secondary amines. The resulting amides usually contain significant populations of two rotamers, readily distinguished by H-1 NMR spectroscopy. Thus, two complementary sets of Delta delta values are obtained from a single analysis, thereby enhancing the power of the method. A strategy for the MTPA derivatization of (the N-methyl tertiary amine in) the tropane alkaloid, cocaine, is also described. The exceptionally large Delta delta values observed for these MTPA amides make this a valuable and reliable method for assignment of amine configuration (even in some cases where only one diastereomeric MTPA amide is readily available).
作者:Adriana Pianaro、Eduardo G.P. Fox、Odair C. Bueno、Anita J. Marsaioli
DOI:10.1016/j.tetasy.2012.05.005
日期:2012.5
A protocol for rapid access to the relative and absolute configurations of the solenopsins, the venomalkaloids of fireants (Solenopsis spp.), was developed based on chiral capillary gas chromatography. The synthesis of racemic mixtures of 2-methyl-6-alkylpiperidines and the isolation of natural (2R,6R)- and (2R,6S)-2-methyl-6-undecylpiperidines allowed for the standardization of the chromatographic
A procedure‐economical synthesis of 2,6‐trans‐substituted piperidinealkaloids is described. The method consists of Ir and Cu catalyzed reductive alkynylation of N‐benzyllactams and tandem catalytic hydrogenation‐hydrogenolysis.
Solenopsin a, b and analogs and as novel angiogenesis inhibitors
申请人:Bowen Phillip J.
公开号:US20050038071A1
公开(公告)日:2005-02-17
The present invention relates to solenopsin A and its analogs for use as angiogenesis inhibitors. The present compounds unexpectedly exhibit good activity as angiogenesis inhibitors, which find use as antitumor/anticancer agents as well as to treat a number of conditions or disease states in which angiogenesis is a factor.